Apr 5, 2022
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Mar 31, 2022
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment...
Jan 10, 2022
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.
Oct 13, 2021
How do you start an M&A discussion? Locust Walk has conducted an extensive study of mergers and acquisitions in biopharma completed in the past three years and uncovered an interesting trend leaders need to understand: the majority of acquirers only became...
Oct 7, 2021
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Q3 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal...
Apr 28, 2021
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial...
